199 related articles for article (PubMed ID: 19307355)
1. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N; Csajka C; Pascual M; Manuel O; Lamoth F; Meylan P; Aubert JD; Venetz JP; Soccal P; Decosterd LA; Biollaz J; Buclin T
Antimicrob Agents Chemother; 2009 Jul; 53(7):3017-23. PubMed ID: 19307355
[TBL] [Abstract][Full Text] [Related]
2. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.
Pescovitz MD; Rabkin J; Merion RM; Paya CV; Pirsch J; Freeman RB; O'Grady J; Robinson C; To Z; Wren K; Banken L; Buhles W; Brown F
Antimicrob Agents Chemother; 2000 Oct; 44(10):2811-5. PubMed ID: 10991864
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N; Decosterd LA; Meylan P; Pascual M; Biollaz J; Buclin T
Clin Pharmacokinet; 2009; 48(6):399-418. PubMed ID: 19650679
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.
Vezina HE; Brundage RC; Balfour HH
Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients.
Wong DD; van Zuylen WJ; Craig ME; Rawlinson WD
Rev Med Virol; 2019 Mar; 29(2):e2023. PubMed ID: 30556615
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
[TBL] [Abstract][Full Text] [Related]
9. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.
Åsberg A; Bjerre A; Neely M
Pediatr Transplant; 2014 Feb; 18(1):103-11. PubMed ID: 24152053
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration.
Chen B; Hu SS; Rui WB; An HM; Zhai XH; Wang XH; Lu JQ; Shao K; Zhou PJ
J Clin Pharmacol; 2021 Mar; 61(3):328-338. PubMed ID: 32926418
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.
Franck B; Woillard JB; Théorêt Y; Bittencourt H; Demers E; Briand A; Marquet P; Lapeyraque AL; Ovetchkine P; Autmizguine J
Br J Clin Pharmacol; 2021 Aug; 87(8):3105-3114. PubMed ID: 33373493
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
[TBL] [Abstract][Full Text] [Related]
13. Oral Valganciclovir as Preemptive Therapy for Cytomegalovirus Reactivation in Pediatric Hematopoietic Stem Cell Transplant Patients.
Atay D; Erbey F; Akcay A; Dag A; Ozturk G
J Pediatr Hematol Oncol; 2015 Oct; 37(7):543-7. PubMed ID: 26207778
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
15. Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN.
Padullés Caldés A; Colom H; Caldes A; Cerezo G; Torras J; Grinyó JM; Lloberas N
Ther Drug Monit; 2014 Jun; 36(3):371-7. PubMed ID: 24305626
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.
Vaziri S; Pezhman Z; Sayyad B; Mansouri F; Janbakhsh A; Afsharian M; Najafi F
J Res Med Sci; 2014 Dec; 19(12):1185-92. PubMed ID: 25709661
[TBL] [Abstract][Full Text] [Related]
17. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.
Chamberlain CE; Penzak SR; Alfaro RM; Wesley R; Daniels CE; Hale D; Kirk AD; Mannon RB
Am J Transplant; 2008 Jun; 8(6):1297-302. PubMed ID: 18444933
[TBL] [Abstract][Full Text] [Related]
19. Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
Padullés A; Colom H; Bestard O; Melilli E; Sabé N; Rigo R; Niubó J; Torras J; Lladó L; Manito N; Caldés A; Cruzado JM; Grinyó JM; Lloberas N
Antimicrob Agents Chemother; 2016 Apr; 60(4):1992-2002. PubMed ID: 26824942
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.
Ayala E; Greene J; Sandin R; Perkins J; Field T; Tate C; Fields KK; Goldstein S
Bone Marrow Transplant; 2006 May; 37(9):851-6. PubMed ID: 16532016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
